scholarly journals SAT0691 Adherence to disease-modifying drugs in chronic inflammatory rheumatic diseases: several questionnaires, diverse patient characteristics and some efficacious interventions – a systematic literature review

2018 ◽  
Author(s):  
D. Puyraimond-Zemmour ◽  
X. Romand ◽  
M. Lavielle ◽  
A. Molto ◽  
P. Gaudin ◽  
...  
Keyword(s):  
Literature Review ◽  
Rheumatic Diseases ◽  
Systematic Literature Review ◽  
Patient Characteristics ◽  
Inflammatory Rheumatic Diseases ◽  
Disease Modifying Drugs ◽  
Chronic Inflammatory Rheumatic Diseases ◽  
Disease Modifying

scholarly journals Methods to improve medication adherence in patients with chronic inflammatory rheumatic diseases: a systematic literature review

RMD Open ◽  
2018 ◽  
Vol 4 (2) ◽  
pp. e000684 ◽  
Author(s):  
Matthieu Lavielle ◽  
Déborah Puyraimond-Zemmour ◽  
Xavier Romand ◽  
Laure Gossec ◽  
Eric Senbel ◽  
...  
Keyword(s):  
Medication Adherence ◽  
Literature Review ◽  
Rheumatic Diseases ◽  
Systematic Literature Review ◽  
Lupus Erythematosus ◽  
Connective Tissue Diseases ◽  
Educational Interventions ◽  
Inflammatory Rheumatic Diseases ◽  
Improve Medication Adherence ◽  
Chronic Inflammatory Rheumatic Diseases

ObjectiveLack of adherence to treatment is frequent in chronic inflammatory rheumatic diseases and is associated with poorer outcomes. The objective of this study was to describe and evaluate interventions that have been proposed to enhance medication adherence in these conditions.MethodsA systematic literature review was performed in Pubmed, Cochrane, Embase and clinicaltrials.gov databases completed by the rheumatology meeting (ACR, EULAR and SFR) abstracts from last 2 years. All studies in English or French evaluating an intervention to improve medication adherence in chronic inflammatory rheumatic diseases (rheumatoid arthritis (RA), spondyloarthritis (SpA), crystal related diseases, connective tissue diseases, vasculitis and Still’s disease) were included. Interventions on adherence were collected and classified in five modalities (educational, behavioural, cognitive behavioural, multicomponent interventions or others).Results1325 abstracts were identified and 22 studies were finally included (18 studies in RA (72%), 4 studies in systemic lupus erythematosus (16%), 2 studies in SpA (8%) and 1 study in gout (4%)). On 13 randomised controlled trials (RCT) (1535 patients), only 5 were positive (774 patients). Educational interventions were the most represented and had the highest level of evidence: 8/13 RCT (62%, 1017 patients) and 4/8 were positive (50%). In these studies, each patient was individually informed or educated by different actors (physicians, pharmacists, nurses and so on). Supports and contents of these educational interventions were heterogenous.ConclusionDespite the importance of medication adherence in chronic inflammatory rheumatic disorders, evidence on interventions to improve medication adherence is scarce.

Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative

2016 ◽  
Vol 75 (6) ◽  
pp. 965-973 ◽  
Author(s):  
Athan Baillet ◽  
Laure Gossec ◽  
Loreto Carmona ◽  
Maarten de Wit ◽  
Yvonne van Eijk-Hustings ◽  
...  
Keyword(s):  
Cardiovascular Diseases ◽  
Literature Review ◽  
Rheumatic Diseases ◽  
Daily Practice ◽  
Gastrointestinal Diseases ◽  
Inflammatory Rheumatic Diseases ◽  
Dissemination And Implementation ◽  
Consensus Process ◽  
European League Against Rheumatism ◽  
Chronic Inflammatory Rheumatic Diseases

In chronic inflammatory rheumatic diseases, comorbidities such as cardiovascular diseases and infections are suboptimally prevented, screened for and managed. The objective of this European League Against Rheumatism (EULAR) initiative was to propose points to consider to collect comorbidities in patients with chronic inflammatory rheumatic diseases. We also aimed to develop a pragmatic reporting form to foster the implementation of the points to consider. In accordance with the EULAR Standardised Operating Procedures, the process comprised (1) a systematic literature review of existing recommendations on reporting, screening for or preventing six selected comorbidities: ischaemic cardiovascular diseases, malignancies, infections, gastrointestinal diseases, osteoporosis and depression and (2) a consensus process involving 21 experts (ie, rheumatologists, patients, health professionals). Recommendations on how to treat the comorbidities were not included in the document as they vary across countries. The literature review retrieved 42 articles, most of which were recommendations for reporting or screening for comorbidities in the general population. The consensus process led to three overarching principles and 15 points to consider, related to the six comorbidities, with three sections: (1) reporting (ie, occurrence of the comorbidity and current treatments); (2) screening for disease (eg, mammography) or for risk factors (eg, smoking) and (3) prevention (eg, vaccination). A reporting form (93 questions) corresponding to a practical application of the points to consider was developed. Using an evidence-based approach followed by expert consensus, this EULAR initiative aims to improve the reporting and prevention of comorbidities in chronic inflammatory rheumatic diseases. Next steps include dissemination and implementation.

scholarly journals Mortality in Inflammatory Rheumatic Diseases: Lithuanian National Registry Data and Systematic Review

2021 ◽  
Vol 18 (23) ◽  
pp. 12338
Author(s):  
Jolanta Dadonienė ◽  
Greta Charukevič ◽  
Gabija Jasionytė ◽  
Karolina Staškuvienė ◽  
Dalia Miltinienė
Keyword(s):  
General Population ◽  
Life Expectancy ◽  
Literature Review ◽  
Rheumatic Diseases ◽  
Systematic Literature Review ◽  
Causes Of Death ◽  
Connective Tissue Diseases ◽  
Standardized Mortality Ratio ◽  
Inflammatory Rheumatic Diseases ◽  
Total Cohort

Despite significant improvement in survival, rheumatic diseases (RD) are associated with premature mortality rates comparable to cardiovascular and neoplastic disorders. The aim of our study was to assess mortality, causes of death, and life expectancy in an inflammatory RD retrospective cohort and compare those with the general population as well as with the results of previously published studies in a systematic literature review. Patients with the first-time diagnosis of inflammatory RD during 2012–2019 were identified and cross-checked for their vital status and the date of death. Sex- and age-standardized mortality ratios (SMR) as well as life expectancy for patients with inflammatory RDs were calculated. The results of a systematic literature review were included in meta-standardized mortality ratio calculations. 11,636 patients with newly diagnosed RD were identified. During a total of 43,064.34 person-years of follow-up, 950 death cases occurred. The prevailing causes of death for the total cohort were cardiovascular diseases and neoplasms. The age- and sex-adjusted SMR for the total cohort was calculated to be 1.32 (1.23; 1.40). Patients with rheumatoid arthritis if diagnosed at age 18–19 tend to live for 1.63 years less than the general population, patients with spondyloarthritis—for 2.7 years less, patients with connective tissue diseases—for almost nine years less than the general population. The findings of our study support the hypothesis that patients with RD have a higher risk of mortality and lower life expectancy than the general population.

Sign in / Sign up

Export Citation Format

Share Document